Newsroom

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Caring for a baby with retinopathy of prematurity (ROP) has never been easy. But mother and social visionary Silke Mader has made it her life’s work to ensure that parents dealing with ROP and other complications today get more support than she did.

Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.

For all too many people living with heart failure, hospitalizations are a recurring part of life, affecting the lives of both patients and their caregivers.

A collaboration in Ghana aims to expand early diagnosis and treatment of people with this inherited illness.

Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.

Christine Hà lost her vision at a young age – and went on to become an award-winning chef.

Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.

We leave the lab to find out what people know about cell and gene therapy.

Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.

AI is already accelerating drug discovery and health delivery. It has great potential to accelerate research, workflow and processes, and even reengineer entire healthcare systems. But what challenges must be addressed first? Shahram Ebadollahi and Ann Aerts share the ideas they discussed at the Intelligent Health summit in Basel this week.